Price alert —
Sign in to get a one-time email the moment ZTS crosses your price. Free accounts included.
Sign in / create a free accountZoetis Inc. is a specialty pharmaceutical company focused on animal health, developing and manufacturing medicines, vaccines, and diagnostic products for pets and livestock. As part of the healthcare sector's drug manufacturing industry, the company serves veterinarians, livestock producers, and pet owners worldwide with products that help maintain and improve animal health.
The stock is currently trading at $77.27, up 3.68% in the most recent session. This price sits well below the 52-week high of $132.49 but modestly above the 52-week low of $71.47, indicating the shares have been under pressure over the past year. The technical picture shows the stock in neutral territory, trading close to its 21-day average. However, the RSI(2) reading of 89.0 suggests the stock is in overbought territory on a very short-term basis, reflecting the sharp single-day gain.
Investors may want to monitor whether the recent bounce continues or if the stock consolidates after this sharp move. Given how far the shares remain from their 52-week high, longer-term price direction and any fundamental developments affecting the animal health industry could be worth watching in the coming weeks.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
below KC1 upper, +0.13 ATR from EMA21 — no notable pattern
- · Counter-trend long in strong downtrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · Aligned with strong downtrend (strong tailwind)
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Our cash-flow model pegs fair value near $48.47 (fair range $48–$110); today's price sits 54% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Quick ratio 1.58 (antifragile)
- ✓ Current ratio 3.03 (antifragile)
- ✓ Positive retained earnings
- ✓ Gross margin 72% (pricing power)
- ⚠ Debt exceeds cash
- ⚠ Debt/equity 3.64 (fragile)
- ⚠ Receivables growing faster than revenue
Price implies ~9% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
ZTS is a $32.1 billion company, priced at 13× last year's earnings, and the stock is trading near the bottom of its 52-week range.
Options idea
See more →Earnings
See more →- Last reported
- 2026-05-07
- EPS (act / est)
- 1.53 / 1.62
- Surprise
- -5.3%
- Next report
- 2026-08-06
About
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and …